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Summary
 
We examined the effectiveness of cytotoxic T lymphocyte–associated antigen 4 (CTLA-4)
blockade, alone or in combination with a granulocyte/macrophage colony-stimulating factor
(GM-CSF)–expressing tumor cell vaccine, on rejection of the highly tumorigenic, poorly im-
munogenic murine melanoma B16-BL6. Recently established tumors could be eradicated in
80% (68/85) of the cases using combination treatment, whereas each treatment by itself showed
little or no effect. Tumor rejection was dependent on CD8
 
1
 
 and NK1.1
 
1
 
 cells but occurred ir-
respective of the presence of CD4
 
1
 
 T cells. Mice surviving a primary challenge rejected a sec-
ondary challenge with B16-BL6 or the parental B16-F0 line. The same treatment regimen was
found to be therapeutically effective against outgrowth of preestablished B16-F10 lung metastases,
inducing long-term survival. Of all mice surviving B16-BL6 or B16-F10 tumors after combi-
nation treatment, 56% (38/68) developed depigmentation, starting at the site of vaccination or
challenge and in most cases progressing to distant locations. Depigmentation was found to occur
in CD4-depleted mice, strongly suggesting that the effect was mediated by CTLs. This study
shows that CTLA-4 blockade provides a powerful tool to enhance T cell activation and mem-
ory against a poorly immunogenic spontaneous murine tumor and that this may involve re-
cruitment of autoreactive T cells.
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R
 
ecent work has shown that unaltered self-antigens ab-
errantly expressed in tumors or expressed in a tissue-
specific fashion can be recognized by T cells isolated from
mice or human cancer patients (for review see references 1
and 2). This finding suggests that autoreactive T cells escape
thymic deletion and reach the periphery, where they can in
some instances be activated and involved in antitumor im-
mune responses. It is generally believed that these autoreac-
tive T cells display relatively low avidity (3) but can be effec-
tive when activated under proper circumstances (4–7). In
addition to the characterization of these self-antigens tar-
geted in antitumor responses, our understanding of the re-
quirements for proper T cell activation have provided possi-
ble explanations for the absence of tumor-specific immunity.
Full activation of naive T cells requires stimulation of the
TCRs by corresponding peptide–MHC complexes, as well
as costimulation through engagement of CD28 by B7.1 or
B7.2 (B7) on the APCs (for review see reference 8). Stimu-
lation of T cells by antigen in the absence of costimulatory
signals can result in unproductive T cell stimulation or T
cell tolerance (9). The lack of expression of B7 by tumor
cells was shown to be one factor that can contribute to
their failure to elicit productive immune responses (10, 11).
CTLA-4 is a second counterreceptor for B7 that plays an
inhibitory role in T cell activation. Accumulating data sug-
gests that CTLA-4 engagement downregulates T cell re-
sponses by raising the threshold of signals needed for effec-
tive T cell activation, although it is possible that CTLA-4
might also play a role in terminating ongoing T cell responses
(12). In vivo
 
,
 
 monoclonal antibodies that block CTLA-4/B7
interactions have been shown to enhance CD4
 
1
 
 T cell ex-
pansion in response to a variety of stimuli, including peptide
antigens, superantigen, and parasites, and can exacerbate
and accelerate autoimmune disease in murine models of di-
abetes and experimental autoimmune encephalitis (for re-
view see reference 12). It has been reported that blockade
of CTLA-4/B7 interactions prevents induction of periph-
eral T cell tolerance upon vaccination with peptides under 
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tolerogenic conditions, suggesting that CTLA-4 might be
actively involved in the induction of anergy (13).
We have previously shown that CTLA-4–blocking anti-
bodies accelerate rejection of B7-transfected tumor cells and
can induce rejection of large, established B7-negative tumors
(14). When applied to a variety of tumor models, we found
that susceptibility to anti–CTLA-4–induced rejection corre-
lated with susceptibility to B7-induced rejection (Leach,
D.R., manuscript in preparation; reference 15). This suggests
that susceptibility to CTLA-4–induced regression is related
to the inherent immunogenicity of the tumor. Thus, immu-
nogenic tumors such as the fibrosarcoma Sa1/N, 51BLim10,
RENCA, and the prostate carcinoma TRAMP/C1 were
completely rejected by injection of CTLA-4–blocking anti-
bodies, whereas outgrowth of poorly immunogenic tumors
such as the melanoma B16-BL6 or the mammary tumor SM1
was minimally affected (14, 16; Leach, D.R., manuscript in
preparation). Synergy with a GM-CSF tumor cell vaccine
was demonstrated in the case of the SM1 tumor (17). Al-
though these studies did not directly demonstrate enhanced
tumor-specific T cell activity as a result of CTLA-4 block-
ade
 
, 
 
in vivo depletion experiments demonstrated that both
CD4
 
1
 
 and CD8
 
1
 
 T cells were required for rejection of the
immunogenic tumors 51BLim10, Sa1/N, and SM1 (17).
NK1.1
 
1
 
 cells were found to also play an intriguing but not
yet defined role in the eradication of TRAMP/C1 by
CTLA-4 (Hurwitz, A.A. and J.P. Allison, unpublished ob-
servations).
In this study, we show that the combination of CTLA-4
blockade and GM-CSF–producing vaccines is therapeuti-
cally effective against the highly tumorigenic and poorly
immunogenic melanoma B16-BL6 in a mechanism depen-
dent on CD8
 
1
 
 and NK1.1
 
1
 
 cells but independent of
CD4
 
1
 
 T cells. Mice cured from established subcutaneous
B16-BL6 tumors are immune to rechallenge with B16-
BL6 or the parental line B16-F0 after 4 mo. We further
show that B16-F10 pulmonary metastases can be eradicated
by the combination treatment and that metastatic lesions
from these mice show extensive infiltration by mononu-
clear cells. In both the subcutaneous and metastatic mela-
noma models, we found that surviving mice developed
depigmentation, indicating that autoimmunity directed
against pigmented cells was concurrently induced. As ani-
mals depleted of CD4
 
1
 
 T cells also developed depigmenta-
tion, it is very likely that this autoimmune phenomenon is
induced by CD8
 
1
 
 T cells directed against pigmentation an-
tigens. This model is well suited to studying the signifi-
cance of autoreactive CD8
 
1
 
 T cells in antitumor responses
as well as investigating the role of CTLA-4 in peripheral
tolerance in a preclinical setting relevant to the immuno-
therapy of cancer.
 
Materials and Methods
 
Mice.
 
C57BL/6 female mice (obtained from Charles River
Labs/National Cancer Institute) were maintained and treated in
accordance with National Institutes of Health and American As-
sociation of Laboratory Animal Care regulations and used for tu-
 
mor experiments when 8–12 wk old. All subcutaneous injections
were performed after mice inhaled of the anaesthetic methoxy-
flurane.
 
Antibodies.
 
Generation and purification of the hamster anti-
murine CTLA-4 antibody 9H10 has been described in previous
work (18). Similarly, GK1.5 (anti-CD4), 2.43 (CD8), PK136
(NK1.1), and 116.3 (Lyt2.1; rat IgG, obtained from B.J. Fowlkes,
National Institute of Allergy and Infectious Diseases, Bethesda, MD)
were prepared in our laboratory as ascites or purified from super-
natant using standard procedures. Mouse IgG and hamster IgG
were purchased from Jackson ImmunoResearch Labs., Inc., and
rat IgG was from Sigma Chemical Co. RM4.4–PE (CD4), anti-
CD8b2–PE, and DX5 (pan-NK) were obtained from PharMingen
and were used to confirm depletions of the relevant population.
 
Cell Lines and GM-CSF Gene Transduction.
 
B16-BL6, B16-F10
(obtained from Dr. I. Fidler, MD Anderson Cancer Center,
Houston, TX), B16-F0 (American Type Culture Collection), and
DC2.4 (19) were cultured in DMEM supplemented with 1 U/ml
penicillin, 1 
 
m
 
g/ml streptomycin, 50 
 
m
 
g/ml gentamycin, 2 
 
m
 
M
 
l
 
-glutamine, and 8% FCS (hereafter referred to as complete
DMEM). The C57Bl/6-derived tumor cell lines EL4 (thymoma)
and MC38 (colorectal carcinoma; obtained from Dr. N. Restifo,
National Cancer Institute, Bethesda, MD) were maintained in
RPMI supplemented with antibiotics, 
 
l
 
-glutamine, 20 
 
m
 
M 
 
b
 
-ME,
and 8% FCS. GM-CSF–producing B16-BL6 and B16-F10 were
obtained by retroviral transduction (20). GM-CSF production
by short-term lines (F10) or clones (BL6) was tested by ELISA
using commercially available antibodies to murine GM-CSF
(PharMingen). Clones BL6/GM-E, BL6/GM-18, BL6/GM-45,
BL6/GM-52 (producing 5, 20, 40, or 50 ng GM-CSF/10
 
6
 
 cells/
24 h, respectively), and the line F10/g (producing 30–40 ng/10
 
6
 
cells/24 h) were cultured using complete DMEM. GM-CSF pro-
duction was routinely confirmed in vitro during the course of
vaccination experiments.
 
Subcutaneous Challenge and Treatment Experiments.
 
Mice were
shaved on the back and challenged subcutaneously with 10
 
4
 
 B16-
BL6 cells in PBS. At the same day or later as indicated, treatment
was initiated by injecting 10
 
6
 
 irradiated (16,000 rads) GM-CSF–
producing cells (in PBS) subcutaneously into the left flank and re-
peated 3 and 6 d later. The vaccine consisted of a 1:1 mixture of
clones BL6/GM-E and BL6/GM-18. Treatment with 9H10 or
control hamster IgG was started simultaneously or 3 d later with
similar results. Antibodies were delivered intraperitoneally at 100 
 
m
 
g
in PBS, usually followed by two 50-
 
m
 
g injections every 3 d. Tu-
mor growth was scored by measuring perpendicular diameters.
Mice were killed when the tumors displayed severe ulceration or
reached a size of 300 mm
 
2
 
. Depletion of T or NK cells was ac-
complished by injection of the relevant antibodies (500 
 
m
 
g, i.p.)
7, 6, and 5 d before tumor challenge and maintained by injec-
tions every 10 d during the experiment. Depletions were con-
firmed in lymph nodes and spleens 1 d before challenge by flow
cytometry using noncross-reactive antibodies. Routinely, 
 
,
 
1%
CD4
 
1
 
 T cells, CD8
 
1
 
 T cells, or NK1.1
 
1
 
 cells were detected in
lymph nodes (after CD4 or CD8 depletion) or spleens (NK1.1
depletion), whereas mice treated with control antibodies (mouse
IgG, rat IgG, or 116.3) demonstrated unchanged lymphocyte pro-
files as compared with untreated mice.
 
Treatment of Lung Metastases.
 
To establish lung metastases, mice
were injected intravenously with 5 
 
3
 
 10
 
4
 
 or 10
 
5
 
 B16-F10 cells.
Treatment using irradiated F10/g cells and antibodies was started
after 24 h, following the same protocol as outlined for treatment
of subcutaneous tumors. After 25 d, lungs were harvested from
each treatment group and surface metastases were counted using 
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a dissection microscope. Paraffin-embedded lung sections were
stained with hematoxylin–eosin using standard procedures. For
survival experiments, 5 
 
3
 
 10
 
4
 
 B16-F10 cells were injected intra-
venously and treatment was started the next day.
 
Generation of CTL Cultures and IFN-
 
g
 
 Release Assay.
 
Spleens
were harvested from mice rejecting B16-BL6 and restimulated in
vitro with B16-BL6/B7.1 or a mixture of B16-F0 and the den-
dritic cell line DC2.4 after overnight coculture. 5 
 
3
 
 10
 
6
 
 
 
spleen
cells were mixed with 10
 
5
 
 irradiated (16,000 rads) stimulator cells,
and recombinant human IL-2 was added to a final concentration
of 30 IU/ml. After 7 d, cells were collected and purified by His-
topaque (Sigma-Aldrich) gradient centrifugation. Live cells (2.5 
 
3
 
10
 
5
 
 per well) were stimulated with target cells (5 
 
3
 
 10
 
4
 
 per well)
in 96-well round-bottom plates for 24 h, after which supernatant
was collected and tested for the presence of IFN-
 
g
 
 by sandwich
ELISA (PharMingen).
 
Results
 
CTLA-4 Blockade Together with GM-CSF–producing Cellu-
lar Vaccines Causes Rejection of Established B16-BL6 Tumors.
 
B16-BL6 was originally derived from the spontaneous murine
melanoma cell line B16-F0 by in vivo selection for inva-
siveness (21). Both the parental line and its variant express
low levels of H-2K
 
b
 
 and D
 
b
 
, and MHC class II is undetect-
able by flow cytometry in vitro and ex vivo (data not shown).
Vaccination with irradiated B16-BL6 does not protect
against subsequent challenge with live B16-BL6 cells, nor
does B7.1 expression result in any significant change in tu-
mor growth in vivo (20, 22; our unpublished results). By
these criteria, B16-BL6 is a very poorly immunogenic tu-
mor. In previous experiments, we had found that CTLA-4
blockade was not therapeutically effective against poorly
immunogenic tumors such as B16-BL6. We also found that
vaccination with irradiated B16-BL6 cells in combination
with anti–CTLA-4 was ineffective (data not shown). We
hypothesized that this might be due to insufficient presen-
tation of tumor antigens by host APCs. Therefore, we
chose to combine CTLA-4 blockade with GM-CSF–pro-
ducing irradiated B16-BL6 whole cell vaccine, which was
described by others as the most effective prophylactic vac-
cine against B16 (20) and augmented immunity against
SM1 (17). Presumably, GM-CSF production at the site of
vaccination might attract host APCs and enhance their
function in vivo. C57BL/6 mice were challenged with 10
 
4
 
B16-BL6 cells subcutaneously and subsequently treated
starting on the same day or 4–12 d later. A representative
experiment is shown in Fig. 1. Administration of anti–
CTLA-4 antibody 9H10 or control hamster IgG by them-
selves had no effect on growth of B16-BL6 tumors. Vacci-
nation with irradiated GM-CSF–producing B16-BL6 cells
along with control antibody delayed growth when initiated
at the time of tumor implantation but had no effect when
treatment was delayed. However, the combination of
GM-CSF–producing vaccine and CTLA-4 blockade in-
duced rejection of all tumors injected the same day or 4 d
earlier. One of five mice carrying a day 8 B16-BL6 tumor
rejected a small palpable tumor after combination treatment
including CTLA-4 blockade. The growth of tumors estab-
lished 12 d earlier was also delayed by the combination
treatment, although rejection was not obtained. When the
data from a series of 10 experiments were combined, an
overall success rate of combination treatment of 80% was
achieved (68/85 mice cured) when treatment was begun at
day 0 or 4 d after tumor implantation (Table I). These re-
sults corroborate the finding that CTLA-4 blockade and
GM-CSF–producing vaccines act synergistically to cause
rejection of poorly immunogenic tumors (17).
A single dose of GM-CSF–producing vaccine adminis-
tered on the same day as tumor challenge was sufficient to
eradicate tumors in all of the mice when combined with
CTLA-4 blockade (Fig. 2). Similarly, a single dose of anti–
CTLA-4 after three vaccinations with GM-CSF–produc-
ing cells was sufficient to induce B16-BL6 rejection (not
shown). GM-CSF production by the vaccine was found to
Figure 1. Successful treatment of
preestablished B16-BL6 using anti–
CTLA-4 and GM-CSF–producing
BL6 vaccine. C57BL/6 female mice
(five per group) were injected with
104 B16-BL6 cells subcutaneously
on the back, on the same day (A) or
4, 8, or 12 d (B–D) before treatment
was started. Treatment consisted of
three consecutive injections (in a
6-d time frame as indicated in Mate-
rials and Methods) of anti–CTLA-4
antibody 9H10 intraperitoneally
(d), control hamster IgG (100, 50,
50 mg; s), or 106 irradiated BL6/g
cells subcutaneously, in combination
with 9H10 (j) or hamster IgG (u).
Tumor growth (mm2) was scored by
measuring perpendicular diameters
and was averaged for all mice within
each group. In some treatment
groups, only a fraction of the mice
(indicated between brackets) devel-
oped a tumor. 
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be critical for the synergistic effect, as vaccination with irra-
diated untransduced B16-BL6 cells in combination with
anti–CTLA-4 antibodies was not effective, as had been
found previously for synergistic treatment of SM1 (data not
shown; reference 17).
 
Combination of CTLA-4 Blockade and GM-CSF–producing
Vaccines Induces Effective Immunity to Rechallenge with B16-BL6.
 
To determine whether mice cured from the initial chal-
lenge of B16-BL6 had developed immunity to rechallenge,
surviving mice received a second challenge of 2 
 
3
 
 10
 
4
 
Table I.
 
Combination Treatment of B16-BL6 Using Anti–CTLA-4 Plus GM-CSF–producing Vaccine
 
Experiment
no.
B16-BL6
Day of
challenge
Treatment
schedule
 
*
 
Fraction of mice responding per treatment group
Depigmentation
 
‡
 
(fraction of
responding mice)
Control
IgG Anti–CTLA-4
BL6/GM-CSF
plus control IgG
BL6/GM-CSF
plus anti–CTLA-4
1 0 A 0/10 — — 7/9 4/7
2 0 A 0/5 0/5 2/5 5/5 3/5
B 5/5 3/5
C 5/5 1/5
3
 
2
 
4 A 0/5 0/5 0/5 3/5 1/3
4 0 A 0/5 — 0/5 6/8 3/6
D 2/5 3/5 2/3
5 0 E 0/5 0/5 0/5 2/5 2/2
F 2/5 3/5 2/3
6 0 A 0/5 — — 6/10 4/6
7 0 A 0/5 0/5 1/5 4/5 1/4
8 0 A 0/5 0/5 0/5 9/9 6/9
9
 
2
 
4 A 0/5 0/5 0/5 5/5 3/5
10 0 A 0/5 0/5 1/5 5/5 3/5
Total number of mice responding: 0/55 0/35 8/50
 
§
 
68/85
 
§
 
36/68
Percentage: 0 0 16 80 56
 
*
 
Treatment regimen A: 10
 
6
 
 irradiated GM-E plus GM-18, administered on days 0, 3, and 6 subcutaneously, plus 100 
 
m
 
g 9H10 or control hamster
IgG (day 0) and 50 
 
m
 
g 9H10 (days 3 and 6); B: vaccine on days 0 and 3, then as in A; C: vaccine on day 0 only, then as in A; D: vaccine on days 0,
6, 20, 34, 48, 62, and 76, then rest as in A; E: clone GM-45 instead of GM-E plus GM-18; F: clone GM-52 instead of GM-E plus GM-18.
 
‡
 
Depigmentation visible as outgrowth of nonpigmented coat, appearing between 4 and 8 wk after treatment.
 
§
 
Responding fraction of mice is significantly different: 
 
P
 
 
 
,
 
 0.000001 (two-sided 
 
t
 
 test).
Figure 2. A single dose of GM-CSF–producing vaccine
cooperates with CTLA-4 blockade to induce 100% cure of
B16-BL6. Mice were inoculated subcutaneously with 104
B16-BL6 cells. On the same day, combination treatment
was initiated using triple BL6/g vaccine (days 0, 3, and 6)
combined with either hamster IgG (100, 50, 50 mg on days
3, 6, and 9; u) or anti–CTLA-4 (j). Control treatments
consisted of antibody injections alone: hamster IgG (s) or
anti–CTLA-4 (d). Also, anti–CTLA-4 treatment was
combined with a single (m) or double injection (r) of the
BL6/g vaccine. Average tumor size was calculated for all
mice within a treatment group (mm2). The fraction of
mice developing tumors is shown between brackets. 
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B16-BL6 on the left flank 128 d after the primary chal-
lenge. Also, resistance to the parental B16-F0 melanoma
cell line was tested by injecting 2 
 
3
 
 10
 
4
 
 cells into the right
flank. Naive age-matched control mice grew both tumors
and required euthanasia within 30 d. All mice cured from a
primary challenge with B16-BL6 rejected B16-F0. Within
the first experiment, the two mice that had rejected the
primary challenge after BL6/g vaccination alone were un-
able to reject a secondary B16-BL6 challenge (Table II). In
contrast, seven out of nine mice that received BL6/g vac-
cine plus anti–CTLA-4 also rejected B16-BL6 (Table II).
In two rechallenge experiments combined, 20/24 mice
cured from B16-BL6 by combination treatment were im-
mune to secondary challenge with B16-BL6, and 11 mice
were resistant to rechallenge with B16-F0. Only four of
eight mice cured upon vaccination with GM-CSF–produc-
ing cells alone were resistant to rechallenge, but the few
mice surviving a primary tumor after treatment with BL6/
GM-CSF vaccine alone did not allow any conclusion to be
drawn as to the possible enhancement of memory forma-
tion by anti–CTLA-4 (
 
P
 
 
 
5 
 
0.062, NS; Table II). Although
immunity to rechallenge with B16-BL6 was not found in
100% of mice cured by the combination treatment, the fact
that B16-F0 was rejected by all suggests that mice surviving
a primary challenge with B16-BL6 had mounted adequate
memory to an antigen(s) shared between the parental line
and its more invasive variant.
 
CD8
 
1
 
 and NK1.1
 
1
 
 but not CD4
 
1
 
 Cells Are Required for
Combination Treatment of B16-BL6.
 
To determine the in-
volvement of T and NK cells in the rejection of B16-BL6,
mice were depleted of CD4
 
1
 
, CD8
 
1
 
, or NK1.1
 
1
 
 cells be-
fore tumor challenge. Treatment was started on the same
day as tumor implantation following the general schedule of
 
three simultaneous injections of vaccine and anti–CTLA-4.
Depletion of CD8
 
1
 
 cells abrogated the effect of treatment
(Table III;
 
 P 
 
5 
 
0.017 compared with control rat IgG).
Mice depleted of NK1.1
 
1
 
 cells were also largely unable to
reject their tumors (8/10). We observed that the tumor-
bearing, NK-depleted mice had developed multiple tumors
at the site of challenge, suggesting that NK cells could be
involved in the first line of defense against the MHC class
I
 
lo
 
 B16-BL6 challenge. Surprisingly, CD4
 
1
 
 T cells were
not required for tumor rejection. In fact, 80% of the CD4-
depleted mice rejected their tumors after treatment with
anti–CTLA-4 and GM-CSF vaccine under suboptimal
conditions where 50–60% of the control groups rejected
B16-BL6 (Table III). Depletion of both CD4
 
1
 
 and CD8
 
1
 
cells abolished the therapeutic effect. It is apparent that CD8
 
1
 
T cells and, most likely, NK1.11 cells are necessary for
rejection of B16-BL6 using CTLA-4 blockade and GM-
CSF–producing vaccines. Activation of CD81 T cells in-
volved in rejection of B16-BL6 does not appear to be de-
pendent on CD4 help in this system.
Table II. Treatment of B16-BL6 Using Anti–CTLA-4 
Facilitates Development of Memory to Rechallenge
Primary treatment
Tumor incidence at 
secondary challenge
B16-BL6 B16-F0
Experiment 1 (rechallenge
on day 128)
BL6/GM plus hamster IgG 2/2 0/2
BL6/GM plus anti–CTLA-4 2/9* 0/9
None 5/5 5/5
Experiment 2 (rechallenge on
day 100–130)
BL6/GM plus hamster IgG 2/6 —
BL6/GM plus anti–CTLA-4 2/15* —
None 5/5 —
*Two experiments combined: 20/24 mice protected from rechallenge
after BL6/GM-CSF plus anti–CTLA-4, versus 4/8 after BL6/GM-CSF
plus control IgG; P 5 0.062 (NS; two-sided t test).
Table III. Involvement of Lymphocyte Subsets in Rejection of 
B16-BL6 through Cotreatment with Anti–CTLA-4 and 
BL6/GM Vaccine
Depletion
B16-BL6
tumor take* Remarks
CD4 2/10‡§ Depigmentation
(4/8 survivors)
CD8 9/10i —
CD4 plus CD8 5/5 —
NK1.1 8/10¶ Multiple tumors
developed at
injection site, no
depigmentation
Control mouse IgG 5/10 Depigmentation
(3/5 survivors)
Control rat IgG 4/10 Depigmentation
(4/6 survivors)
No depletion 5/10 Depigmentation
(3/5 survivors)
No depletion, no treatment† 10/10 —
Depletion of lymphocyte subsets was achieved by injecting depleting
antibodies GK1.5 (anti-CD4), 2.43 (CD8), PK136 (NK1.1), or control
antibodies at days 28, 27, 26, and every 7 (GK1.5) to 10 d thereafter.
Depletion was checked at day 21. Results are compiled from two ex-
periments.
*Live B16-BL6 challenge on day 0 was followed by anti–CTLA-4 and
BL6/GM vaccination on days 0, 3, and 6.
‡Fraction of mice unable to reject the B16-BL6 challenge.
§CD4 depletion versus rat IgG: P  5 NS; CD4 versus CD8; P  5
0.00054 (two-sided t test).
iCD8 versus rat IgG: P 5 0.017 (two-sided t test).
¶NK1.1 versus control mouse IgG: P 5 NS.
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Generation of B16-specific T Cells Is Strongly Enhanced by
CTLA-4 Blockade In Vivo. To determine if tumor-reac-
tive T cells were induced by the combination therapy,
mice were immunized with BL6/g plus anti–CTLA-4 or
control IgG and challenged with B16-BL6 after 4 wk. 10 d
after challenge, spleens from four mice in each group were
pooled and restimulated with B16-BL6/B7.1 or a mixture
of B16-F10 and the dendritic cell line DC2.4 (19). After
one round of restimulation in vitro, specific IFN-g release
was tested using different variants of B16 and two unrelated
tumor cell lines expressing the H-2b haplotype, the thy-
moma EL4 and the colorectal carcinoma MC38. As shown
in Fig. 3, T cells from mice vaccinated with BL6/g in the
presence of control hamster IgG produced very low levels
of IFN-g in this assay. T cells from mice treated with anti–
CTLA-4 in vivo had greatly enhanced B16-specific IFN-g
secretion. These results indicate that CTLA-4 blockade
during vaccination with BL6/g specifically enhances reac-
tivity toward an antigen (or antigens) expressed by B16 and
its variants. In addition, all splenocyte cultures established
from mice that were long-term (3–10 mo) survivors after
combination treatment were found to specifically react
with B16 and its variants, as tested by IFN-g release after one
round of restimulation in vitro (data not shown). Successful
rejection of B16-BL6 coincides with the generation of tu-
mor-specific T cell activity.
Suppression of B16-F10 Lung Metastases and Induction of Long-
Term Survival by Combination Treatment. We next sought to
determine whether anti–CTLA-4 combined with vaccina-
tion would be effective against metastatic disease. 105 B16-
F10 cells (selected for metastasis exclusively to the lungs)
were injected intravenously, and treatment was started 1 d
later. On day 25, mice were killed and surface lung metastases
were counted. Treatment with anti–CTLA-4 alone did not
have any appreciable effect on the lung metastasis count as
compared with control IgG (Table IV). Immunization with
F10/g reduced the number of metastases in a few mice.
Treatment of F10/g-vaccinated mice with anti–CTLA-4
further suppressed lung colonization and completely inhib-
ited pulmonary metastases in two of five mice sampled.
Histological analysis of these lung samples demonstrated
that CTLA-4 blockade in combination with F10/g vacci-
nation was associated with infiltration of mononuclear cells
in all of the metastases stained and observed in three of the
five tumor-bearing lungs (the two remaining sets of lungs
were found to be tumor free) (Fig. 5). Neither anti–CTLA-4
nor F10/g vaccination alone resulted in lymphocytic infil-
tration in lung tumors or surrounding tissue. A few poly-
morphonuclear cells were observed in the smaller metastases
from mice vaccinated with F10/g in the presence of con-
trol IgG, but there were no extensive infiltrates in larger le-
sions in any of the control groups. The observation that the
combination therapy had at least some effect in enhancing
infiltration and reducing lung metastases led us to test its ef-
fectiveness in increasing survival, as shown in Fig. 4. Mice
challenged with 5 3 104 B16-F10 cells and treated with
control hamster IgG all (10/10) succumbed to lung failure
due to extensive metastatic disease by day 75 after injec-
tion. Anti–CTLA-4 by itself prolonged survival, as did vac-
cination with F10/GM. However, 13/13 mice receiving
Figure 3. Anti–CTLA-4 enhances
IFN-g production by B16-specific T
cells induced in vivo. Mice (four per
group) were vaccinated with irradi-
ated BL6/g (106 per mouse) and
cotreated with control hamster IgG
(A) or anti–CTLA-4 (B). After 4 wk,
mice were challenged with 2 3 104
B16-BL6, and 10 d later, splenocytes
were pooled and restimulated in vitro
using B16-BL6/B7.1 (open bars) or a
mixture of B16-F10 and DC2.4 den-
dritic cells (filled bars). On day 8, cul-
tures were tested for tumor-specific
IFN-g release as described in Materi-
als and Methods. Targets included
B16 sublines -F0, -F10, and -BL6, as
well as unrelated H-2b tumors EL4
and MC38.
Table IV. Reduced Number of B16-F10 Lung Metastases after 
Combination Treatment with Anti–CTLA-4 and F10/GM Vaccine
Treatment of
lung metastases Lung metastasis count
Control hamster IgG .200, .200, .200, 25, 16
Anti–CTL-4 .200, .200, .200, .200, .200
Hamster IgG plus
F10/GM vaccine .200, .200, 35, 49, 4
Anti–CTLA-4 plus
F10/GM vaccine 87, 28, 6, 0, 0*
B16-F10 (105, i.v.)-induced lung metastases were treated with hamster
IgG, 9H10, and F10/GM vaccine in combination with either antibody
on days 1, 4, and 7 after challenge. Surface lung metastases were
counted under a dissecting microscope 25 d after inoculation. Counts
are shown for each individual mouse; all counts over 200 were scored
as .200.
*F10/GM plus CTLA-4 versus control hamster IgG: P 5 0.057 (NS;
two-sided t test).361 van Elsas et al.
the combination treatment were still alive by day 80 (Fig.
4). Lungs taken from these surviving mice did not demon-
strate metastatic lesions on their surfaces. This is the first
demonstration that CTLA-4 blockade in vivo is therapeuti-
cally effective against disseminated disease.
Mice Surviving Subcutaneous B16-BL6 Tumors or B16-F10
Lung Metastases Develop Skin and Hair Depigmentation.
Within 4–8 wk after challenge, 56% (38/68 cured mice) of
the surviving mice developed depigmentation, starting at the
sites of vaccination (left flank) and challenge (back) (Fig. 6 A).
Moreover, depigmentation was observed at the site of vacci-
nation in a similar proportion of mice surviving B16-F10
lung metastases (Fig. 6 B). Rejection of a B16-BL6 tumor es-
tablished 8 d before start of treatment (Fig. 1) induced fast and
progressive depigmentation appearing within 25 d after
challenge and spreading to distant sites, indicating that a rel-
atively strong antitumor response resulted in rapid manifesta-
tion of progressive depigmentation (Fig. 6 C). Depigmenta-
tion did occur in mice that received combination treatment
in a prophylactic setting but at reduced frequency (not
shown).  Interestingly, depigmentation was not dependent on
the presence of CD41 T cells, as four of eight CD4-depleted
mice rejecting their tumors also developed progressive depig-
mentation (Table III). In some cases, tumor-bearing mice
(moribund despite treatment with anti–CTLA-4 and BL6/
GM) were found to develop small areas of hair depigmenta-
tion at the site of progressive tumor growth. Depigmentation
was never observed in the mice that were treated by BL6/
GM-CSF vaccination without CTLA-4 blockade or in any of
the other treatment groups. These findings suggest that
CTLA-4 blockade allows for the activation of autoreactive
lymphoid cells that are involved in rejection of a tumor de-
Figure 4. Mice bearing B16-F10 lung me-
tastases show enhanced survival when treated
with anti–CTLA-4 and F10/g vaccine. B16-
F10 cells (5 3 104 per mouse) were injected
into the tail vein and 24 h later, treatment was
started using control hamster IgG (10 mice, s),
anti–CTLA-4 antibody 9H10 (9 mice; d), irra-
diated F10/g (106 subcutaneously) in combina-
tion with hamster IgG (10 mice; u) or 9H10
(13 mice; j) on days 1, 4, and 7, according to
the dosing schedule used for subcutaneous tu-
mors (see Fig. 1 legend). Mice were followed
for survival, and in some subjects death due to
extensive pulmonary metastasis was confirmed
by harvesting lungs postmortem.
Figure 5. B16-F10 metastases
demonstrate lymphocytic infil-
tration after treatment with anti–
CTLA-4 and F10/g vaccine.
Mice injected with 105 B16-F10
intravenously and treated with
control hamster IgG (A), 9H10
(B), or F10/g vaccine in combi-
nation with either hamster IgG
(C) or 9H10 (D) on days 1, 4,
and 7, as outlined in the Fig. 4
legend. On day 25, lungs were
harvested, fixed in 10% neutral-
buffered formalin, and processed
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rived from the melanocytic lineage and may also mediate re-
jection of normal pigment-containing cells in the skin and
hair follicles expressing pigmentation antigens.
Discussion
In this study, we show that administration of anti–CTLA-4
antibody, when combined with an irradiated GM-CSF–pro-
ducing tumor cell vaccine, results in rejection of previously
established primary tumors and resistance to secondary
challenge in mice inoculated with the nonimmunogenic
melanoma B16-BL6. Similarly, this combination treatment
led to the eradication of B16-F10 lung metastases. The com-
bination treatment induced massive infiltration of mono-
nuclear cells into the remaining lung metastases. Tumor re-
jection by the combination treatment was reflected by an
enhancement of B16-specific T cell responses in vitro. Af-
ter tumor eradication, 56% of the surviving mice devel-
oped depigmentation of the hair (Table I). Both tumor re-
jection and subsequent depigmentation were dependent on
the presence of CD81 T cells and NK1.11 cells but did not
require CD41 T cells.
We have found that treatment with anti–CTLA-4 is suf-
ficient to obtain rejection of many, but not all, experimen-
tal tumors (14, 16, 17). The effectiveness of CTLA-4 block-
ade appears to correlate with that of B7-positive tumor cell
vaccines, suggesting that it is most effective against tumors
with a significant degree of intrinsic immunogenicity. The
lack of therapeutic effectiveness of CTLA-4 blockade by it-
self on B16-BL6 can most likely be attributed to the poor
capacity of this tumor to provide antigens to host APCs.
GM-CSF–transduced tumor cells have been shown to in-
duce potent immunity to a variety of tumors, including B16
(20, 22). The effectiveness of GM-CSF in these systems can
probably be attributed to the capacity of this cytokine to
attract host bone marrow–derived APCs and enhance their
differentiation, thereby increasing their capacity to cap-
ture tumor-derived antigens in the local environment of
the irradiated tumor cell vaccine (23–25). Although this
immunization strategy has been shown to greatly enhance
the immunogenicity of B16 cells and leads to resistance to
subsequent challenge with viable tumor cells, the response
elicited by irradiated GM-CSF tumor cells is only margin-
ally if at all effective in the treatment of preestablished tu-
mors. We obtained tumor rejection in 16% of mice treated
with the vaccine alone (Table I), and then only when it was
administered on the same day as tumor challenge. These re-
sults suggest that GM-CSF vaccine has a limited potential
to elicit an effector cell response of sufficient potency to ob-
tain rejection in tumor-bearing mice. The potency of the
combination of the vaccine and anti–CTLA-4 antibody can
likely be attributed to enhanced cross-priming of T cells by
host APCs by the vaccine, together with a highly potenti-
ated T cell response as a result of the removal of the inhib-
itory effects of CTLA-4 by antibody blockade. This results
in a synergistic enhancement of the T cell response to a
level capable of eliminating the preexisting tumor cell mass.
This could occur as a consequence of activation of a larger
number of naive T cells due to a lowering of the threshold
for activation or a more sustained response due to tempo-
rary removal of signals involved in terminating the response
(12). Rejection is accompanied by long-lived memory, as
indicated by the fact that cured mice reject rechallenge in
the absence of treatment 4 mo after the initial treatment.
Whereas the combination treatment resulted in an over-
all cure rate of 80% in mice treated on day 4 or before, ef-
fectiveness was much lower when initiated at day 8 and
was essentially ineffective at day 12 or later. This is in con-
trast to our previous findings that CTLA-4 blockade by it-
self was quite effective in the treatment of well established
tumors in other model systems. Subcutaneous tumors of
the colon carcinoma 51Blim10 or the fibrosarcoma Sa1N
could be eradicated when antibody was administered be-
ginning as late as 2 wk after tumor inoculation, and com-
plete eradication was obtained even when treatment was
delayed until the tumors reached a size of 100–140 mm2
(Leach, D.R., manuscript in preparation). The difference in
the responses obtained in these experiments and in this
study may be related to the relative antigenicity of the sys-
tems—more immunogenic targets may also be better tar-
gets f or effector T cells than the poorly immunogenic
B16-BL6, which might simply be able to outstrip the
emerging T cell response. It may be that tumors grow be-
yond a critical size than can be effectively dealt with by the
immune response. It is also possible that loss of effectiveness
Figure 6. Rejection of B16-BL6 or B16-F10 as a result of treatment with anti–CTLA-4 and GM-CSF–producing vaccines causes autoimmune skin
and hair depigmentation. After successful treatment for B16-BL6 subcutaneously or B16-F10 intravenously, C57Bl/6 mice developed skin and hair de-
pigmentation. (A) Depigmentation of both sites of vaccination and challenge, after rejection of a day 0 tumor. (B) Progressive depigmentation found in a
mouse rejecting a B16-BL6 subcutaneous tumor, established 8 d before treatment started. (C) Depigmentation at the site of vaccination of a mouse cured
from preestablished B16-F10 lung metastases.363 van Elsas et al.
of the vaccine is a consequence of induction of nonrespon-
siveness or tolerance in tumor-reactive T cells. It has been
reported that treatment with anti–CTLA-4 resulted in re-
jection of two fibrosarcomas when begun 1–2 wk after in-
oculation but that late-stage tumors (7–10 wk) were resis-
tant to treatment (26). This loss of effectiveness was
accompanied by a loss of in vitro antitumor responses, sug-
gestive of deletion or inactivation of T cells. It has also
been shown that growth of a B cell lymphoma engineered
to express influenza hemagglutinin results in the progres-
sive inactivation of adoptively transferred T cells bearing
hemagglutinin-specific TCRs (27). In this system, adminis-
tration of anti–CTLA-4 greatly enhanced T cell priming if
begun before responses were totally lost but could not re-
verse tolerance once established (27a). The basis for loss of
responsiveness of more established B16-BL6 tumors to the
combined treatment regimen remains to be established.
Our results demonstrate that both the therapeutic effect
and the subsequent depigmentation obtained with the com-
bination treatment required CD81 and NK1.11 cells but was
independent of CD41 T cells. The involvement of NK1.11
cells in prophylaxis induced by B16/GM-CSF vaccines has
been previously noted, especially when MHC Class Iio or I2
cells were used (28, 29). It is therefore not surprising that
eradication of B16-BL6 in our model might require
NK1.11 cells. An important contribution of the NK1.11
cells may be to lyse cells in the vaccine, thereby enhancing
antigen uptake by host APCs recruited to the site of vacci-
nation by GM-CSF in the vaccine.
Our previous studies have revealed that tumor rejection
after anti–CTLA-4 treatment, given alone in the case of
immunogenic tumors or together with a GM-CSF–trans-
duced vaccine for a poorly immunogenic mammary carci-
noma, required both CD41 and CD81 cells (14, 17). This
result could be interpreted as indicative of a requirement
for CD41 T cell help for the effective induction of CD81
CTLs. However, several observations have suggested a role
for CD41 T cells in antitumor responses beyond provision
of help for CTLs. Depletion of CD41 or CD81 T cells af-
ter immunization but before tumor challenge abrogates the
ability of irradiated GM-CSF–producing B16 cells to in-
duce protective immunity (20). CD41, but not CD81, T
cells were required for the induction of immunity with a
GM-CSF–expressing, class I MHC–negative tumor cell
vaccine (28). Finally, an extensive analysis using a variety of
knockout mice as hosts has shown that CD41 T cells were
absolutely required for the induction of protective immu-
nity using GM-CSF–expressing B16 cells but that absence
of CD81 T cells resulted in only a partial loss of effective-
ness (22). This, together with the observation that cytokines
elaborated by CD41 T cells resulted in the recruitment and
activation of eosinophiles and macrophages, suggested an
additional role for CD41 T cells in orchestrating CD81
T cell–independent protective mechanisms when GM-
CSF–expressing B16 cell vaccine is used in the setting of
prophylaxis.
In the therapeutic setting, our finding that CD41 T cells
are dispensable for obtaining tumor rejection suggests that
the combination treatment in this system can allow for di-
rect induction of CD81 T cell responses, in agreement
with what has recently been reported for antiparasite re-
sponses (30). One contributing factor might be a high dose
and persistence of antigen due to the use of three doses of
tumor cell vaccine. It is also possible that CTLA-4 block-
ade lowers the threshold of stimulation or costimulation
that is required for activation of naive T cells. It has re-
cently been shown that a very important mechanism of
CD41 T cell help for the generation of CTLs is an en-
hancement of antigen presentation and costimulatory activ-
ity of dendritic cells as a consequence of engagement of
CD40 on the dendritic cell by CD40L on activated CD41
cells (31–33). It is possible that CTLA-4 blockade lowers
the threshold of signals needed for CD81 T cell activation
to a level that can be provided by GM-CSF–stimulated
dendritic cells in the absence of “licensing” by activated
CD41 T cells.
After eradication of B16-BL6 tumors, 56% of the surviv-
ing mice developed depigmentation starting at the sites of
vaccination and challenge and spreading to distant sites.
Loss of coat color indicated that systemic and progressive
autoimmunity had developed toward pigment-bearing cells.
For human melanoma patients, a good correlation between
autoimmune depigmentation and improved clinical response
has been documented (34, 35). Melanoma-associated hy-
popigmentation closely resembles vitiligo, an autoimmune
phenomenon that possibly involves antibody and T cell re-
sponses against melanocyte antigens (36, 37). Genes encod-
ing proteins associated with pigment synthesis or with me-
lanosomes have been cloned and characterized as targets for
CTLs in human melanoma patients (1, 2). Reinfusion of
autologous tumor-infiltrating lymphocytes specifically rec-
ognizing gp100/Pmel-17 or tyrosinase led to tumor regres-
sions in some cases, although the value of targeting such
antigens is unclear from such clinical studies because the
adoptive transfers were performed in the presence of high-
dose systemic IL-2 (38). Apparently, T cell tolerance against
these melanocyte antigens can be broken to induce antitu-
mor reactivity. Currently, several approaches (peptide or
genetic vaccination), to (re-)direct melanocyte-reactive CTLs
against melanoma are clinically evaluated. The consequences
of breaking tolerance to pigment antigens are largely un-
known and could be studied in an appropriate murine
model.
Two murine melanocyte antigens (TRP2 and Pmel-17/
gp100) have been found to serve as CTL antigens in the
immune response to B16 tumors (6, 39). T cell tolerance
toward Pmel-17/gp100 could only be broken by using xe-
nogeneic human gp100. No autoimmune depigmentation
was reported after vaccination with peptide or recombinant
vaccinia virus or after adoptive transfer of specific CTL clones.
In addition to CTLs, potent antibody responses were gen-
erated against gp75/TRP1 by vaccinating naive mice with
recombinant human gp75, hgp75 DNA, human melanoma
cells expressing gp75, or recombinant vaccinia virus ex-
pressing human gp75 but not using murine gp75 formula-
tions (40–42). Apparently, B cell tolerance toward gp75364 Depigmentation after Immunotherapy of B16 Melanoma Using Anti–CTLA-4
was broken by using xenogeneic antigen. Follow-up stud-
ies demonstrated that tumor protection required CD41 and
NK1.11 cells but not CD81 cells, whereas depigmentation
developed in CD42/2 and FcRg2/2 mice in the absence of
tumor protection, suggesting that the phenomena are caused
by different mechanisms (43). It should be noted that
gp75/TRP1 is the most abundant protein in melanocytes
and some melanomas, and it can be detected on the cell
surface (in contrast to the other melanocyte antigens),
which could explain the finding of autoimmune depig-
mentation associated with anti-gp75 antibodies.
In our system, tumor rejection induced by a combina-
tion of the BL6/GM-CSF vaccine and CTLA-4 blockade
was followed by depigmentation, which can occur in the
absence of CD41 T cells. Depigmentation was not ob-
served in any of the small number of mice whose tumors
were rejected after treatment with the vaccine alone, nor was
depigmentation noted in previous studies of GM-CSF/B16
vaccines used for prophylaxis (20, 22). It seems likely that
depigmentation occurs in our system because the GM-CSF
vaccine, when enhanced by CTLA-4 blockade, can elicit
CTLs directed to normal melanocyte antigens expressed by
the tumor cells, and the same cells responsible for tumor
rejection also mediate autoimmune destruction of normal
melanocytes. However, it remains possible that antibodies
to gp75 or other antigens have some role in depigmenta-
tion in intact mice.
In our view, there are at least two nonexclusive explana-
tions for our observation that anti–CTLA-4 antibodies syn-
ergize with BL6/GM-CSF vaccine to induce rejection and
autoimmunity: (a) CTLA-4 blockade greatly increases the
burst size of T cells responding to the GM-CSF vaccine,
thus enhancing the mobilization of effector cells, and (b)
CTLA-4 blockade lowers the threshold for T cell activation,
thereby allowing the recruitment and activation of low-affin-
ity autoreactive T cells that might have escaped central toler-
ance induction. In either case, autoreactive CTLs involved in
tumor rejection could find targets in melanocytes exposed
through local inflammation or skin destruction. Although it is
an unwanted side effect of treatment, depigmentation or viti-
ligo is considered to be an acceptable risk for the treatment of
melanoma in clinical situations. To our knowledge, this re-
port is the first describing T cell–dependent depigmentation
after successful treatment of murine melanoma. Rejection of
B16-BL6 through CTLA-4 blockade plus GM-CSF–pro-
ducing vaccines could serve as a model to study the relation-
ship between tumor immunity and autoimmunity in a setting
relevant to the treatment of human cancer.
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